Literature DB >> 12653854

Production of antineutrophil cytoplasm antibodies derived from circulating B cells in patients with systemic vasculitis.

A R Clayton1, C O S Savage.   

Abstract

The pathogenesis of systemic vasculitis is complex and is likely to involve many mechanisms. In certain systemic vasculitides, autoimmunity plays an important role with autoantibodies developing towards neutrophils, which are termed antineutrophil cytoplasm antibodies (ANCA). There is a growing body of evidence that T cells may contribute to the pathogenesis of ANCA-associated vasculitides. A system was set up to determine whether B cells require T cell help to produce antibodies in a peripheral blood lymphocyte (PBL) culture system enriched for B cells and dendritic cells (DC). As a control, tetanus toxoid (TT) antibody production was detected from individuals not recently immunized with tetanus vaccine when stimulated with TT antigen. Proteinase 3 (PR3) and myeloperoxidase (MPO) antibodies were produced from B cell and DC enriched cultures prior to the addition of antigen in some ANCA-positive patients with high ANCA titres, but not from patients with low ANCA titres or controls. PBMC from individuals recently immunized with tetanus vaccine were also maximally stimulated in that addition of antibody did not enhance antibody production. We conclude that this system supports a role for T cell help in the production of TT antibodies in individuals not immunized recently with tetanus vaccine. However, in patients with ANCA-associated vasculitis and controls recently immunized with tetanus vaccine, circulating B cells are apparently spontaneously producing autoantibody, possibly reflecting a system already maximally driven in vivo, and therefore masking underlying potential T cell-B cell collaboration. Such B cells may be less responsive to regulatory stimuli in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653854      PMCID: PMC1808685          DOI: 10.1046/j.1365-2249.2003.02111.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Peripheral blood T lymphocytes in systemic vasculitis: increased T cell receptor V beta 2 gene usage in microscopic polyarteritis.

Authors:  I J Simpson; M A Skinner; A Geursen; J S Peake; W G Abbott; J D Fraser; C M Lockwood; P L Tan
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

Review 2.  Superantigens: bacterial and viral proteins that manipulate the immune system.

Authors:  M T Scherer; L Ignatowicz; G M Winslow; J W Kappler; P Marrack
Journal:  Annu Rev Cell Biol       Date:  1993

Review 3.  Interactions between leukocytes, the vascular endothelium and autoantibodies in the development of systemic vasculitis.

Authors:  C O Savage
Journal:  Ann Med Interne (Paris)       Date:  1993

Review 4.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

5.  Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers.

Authors:  G N Gephardt; M Ahmad; R R Tubbs
Journal:  Am J Med       Date:  1983-04       Impact factor: 4.965

6.  T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis.

Authors:  R Giscombe; J Grunewald; S Nityanand; A K Lefvert
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

7.  T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG).

Authors:  E Brouwer; C A Stegeman; M G Huitema; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

8.  Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity.

Authors:  W H Schmitt; C Heesen; E Csernok; A Rautmann; W L Gross
Journal:  Arthritis Rheum       Date:  1992-09

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  5 in total

1.  ANCA patients have T cells responsive to complementary PR-3 antigen.

Authors:  Jiajin Yang; David J Bautz; Sofia Lionaki; Susan L Hogan; Hyunsook Chin; Roland M Tisch; John L Schmitz; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

Review 2.  Pharmacological therapy for Wegener's granulomatosis.

Authors:  Eric S White; Joseph P Lynch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Anti-endothelial cell antibodies (AECA) in patients with propylthiouracil (PTU)-induced ANCA positive vasculitis are associated with disease activity.

Authors:  F Yu; M-H Zhao; Y-K Zhang; Y Zhang; H-Y Wang
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

4.  Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.

Authors:  Karina A Keogh; Steven R Ytterberg; Fernando C Fervenza; Kimberly A Carlson; Darrell R Schroeder; Ulrich Specks
Journal:  Am J Respir Crit Care Med       Date:  2005-10-13       Impact factor: 21.405

Review 5.  The potential utility of B cell-directed biologic therapy in autoimmune diseases.

Authors:  D G Arkfeld
Journal:  Rheumatol Int       Date:  2007-10-24       Impact factor: 2.631

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.